Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 519

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

LaBrecque, Douglas R., Abbas, Zaigham, Anania, Frank, Ferenci, Peter, Khan, Aamir G., Goh, Khean-Lee, Hamid, Saeed S., Isakov, Vasily, Lizarzabal, Maribel, Peñaranda, Manuel M., Ramos, Juan F.R., Sarin, Shiv, Stimac, Davor, Thomson, Alan B.R., Umar, Muhammed, Krabshuis, Justus, LeMair, Anton·2014·Journal of Clinical Gastroenterology

Abstract

INTRODUCTION Over the past couple of decades, it has become increasingly clear that nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are now the number 1 cause of liver disease in the western countries. The prevalence of NAFLD has doubled during last 20 years, whereas the prevalence of other chronic liver diseases has remained stable or even decreased. More recent data confirm that NAFLD and NASH play an equally important role in the Middle East, Far East, Africa, the Caribbean, and Latin America. NAFLD is a condition defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. A subgroup of NAFLD patients displays liver cell injury and inflammation in addition to excessive fat (steatohepatitis). The latter condition, designated NASH, is virtually indistinguishable histologically from alcoholic steatohepatitis. While the simple steatosis of NAFLD does not correlate with increased short-term morbidity or mortality, progression of this condition to that of NASH dramatically increases the risks of cirrhosis, liver failure, and hepatocellular carcinoma. The exact cause of NASH has not been elucidated, and it is almost certainly not the same in every patient. Although it is most closely related to insulin resistance, obesity, and the metabolic syndrome, not all patients with these conditions have NAFLD/NASH, and not all patients with NAFLD/NASH suffer from one of these conditions. NASH is a potentially fatal condition, leading to cirrhosis, liver failure, and hepatocellular carcinoma.Table: No title available.Cascades: A Resource-sensitive Approach A gold-standard approach is feasible for regions and countries in which the full scale of diagnostic tests and medical treatment options are available for the management of NASH. However, such resources are not available throughout much of the world. With their diagnostic and treatment cascades, the World Gastroenterology Organisation guidelines provide a resource-sensitive approach.Table: No title available.EPIDEMIOLOGY NASH is an increasingly common chronic liver disease with worldwide distribution that is closely associated with diabetes and obesity, which have both reached epidemic proportions. It is estimated that there are at least 1.46 billion obese adults worldwide. Approximately 6 million individuals in the USA are estimated to have progressed to NASH and some 600,000 to NASH-related cirrhosis. There are significant cultural and geographic differences in the prevalence of obesity. Whereas in most western countries, the preferred body image, especially in women, is very thin with minimal body fat, which is not necessarily true globally. In many other cultures, obesity is considered desirable and also regarded as a distinct sign of prosperity. In the USA, obesity is particularly epidemic in those from lower socioeconomic groups who rely heavily on diets provided by high-fat, high-calorie fast food outlets (junk food). The opposite is true in many poorer countries, where it is the well-to-do, better-educated population that has the highest prevalence of obesity (Table 1).TABLE 1: Estimated Prevalences of NAFLD and NASHDIAGNOSIS Diagnostic Strategy for NASH NASH represents the most severe histologic form of NAFLD, which is defined by fat accumulation in the liver exceeding 5% of its weight. Uniform criteria for diagnosing and staging NASH are still debated. Insulin resistance is related to obesity and is central to the pathogenesis of NAFLD. In addition, oxidative stress and cytokines are important contributing factors, together resulting in steatosis and progressive liver damage in genetically susceptible individuals. The disease can remain asymptomatic for years, or can progress to cirrhosis and hepatocellular carcinoma. Triggers for considering a diagnosis of NASH and starting testing of liver enzymes are: hypertension, type 2 diabetes, sleep apnea, a positive family history, nonblack ethnicity, obesity, hyperlipidemia, and a sedentary lifestyle (Figs. 1–3).Table: No title available.FIGURE 1: Management algorithm for nonalcoholic fatty liver disease. ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index. Based on Rafiq and Younossi.10FIGURE 2: Diagnostic options for NAFLD. ALT indicates alanine aminotransferase; AMA, antimitochondrial antibody; ANA, antinuclear antibody; anti-LKM Ab, anti-liver–kidney microsomal antibody; ASMA, antismooth muscle antibody; AST, aspartate aminotransferase; BMI, body mass index; CT, computed tomography; FBG, fasting blood glucose; GGT, γ-glutamyl transferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; LFT, liver function tests; NAFLD, nonalcoholic fatty liver disease; OGTT, oral glucose tolerance test.FIGURE 3: Algorithm for liver biopsy in patients with suspected nonalcoholic fatty liver disease after exclusion of other liver diseases.Cascade: Options for Diagnosis in Patients With Suspected NAFLD/NASH See Tab

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mcg.0000000000000116

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 519

Metadata

Authors
LaBrecque, D. R., Abbas, Z., Anania, F., Ferenci, P., Khan, A. G., Goh, K.-L., Hamid, S. S., Isakov, V., Lizarzabal, M., Peñaranda, M. M., Ramos, J. F. R., Sarin, S., Stimac, D., Thomson, A. B. R., Umar, M., Krabshuis, J., & LeMair, A.
Venue
Journal of Clinical Gastroenterology
Published
2014-07
Volume
48
Issue
6
Pages
467-473
ISSN
0192-0790 (ISSN-L)
OpenAlex
W1974062643
Cited by
519
References
15
FWCI
40.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. https://app.cochat.ai/papers/10.1097/mcg.0000000000000116
The paper
LaBrecque, D. R., Abbas, Z., Anania, F., Ferenci, P., Khan, A. G., Goh, K.-L., Hamid, S. S., Isakov, V., Lizarzabal, M., Peñaranda, M. M., Ramos, J. F. R., Sarin, S., Stimac, D., Thomson, A. B. R., Umar, M., Krabshuis, J., & LeMair, A. (2014). World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0000000000000116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.